There is strong preclinical evidence that blocking the CD47-SIRPα interaction with an antibody enhances phagocytosis and restricts the growth of tumors in vivo (5, 33, 34) but whether Shp1 loss in tumor-infiltrating immune cells would similarly enhance anti-tumor immunity remains an open question. This evidence concerns the gene PTPN6 and neoplasm.